Have any questions? 706-721-6582 or cts@augusta.edu
- JZP025-101: V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Subjects with Previously Untreated Acute Myeloid Leukemia Study
Clinical Trial
JZP025-101: V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Subjects with Previously Untreated Acute Myeloid Leukemia Study
Patients are being asked to take part in this study because they have previously untreated Acute Myeloid Leukemia (AML). The Sponsor is doing this study to find out whether CPX-351 given in combination with venetoclax, midostaurin or enasidenib is safe and effective when treating subjects with newly diagnosed AML.
Eligibility Criteria
- Male or female, aged 18 years or older, aged 75 years or younger Subjects with newly diagnosed acute myeloid leukemia Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.